Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Johnson & Johnson Add to portfolio

INX:JNJ, Nov 21, 04:24 UTC

Latest INX:JNJ News

Filter your feed

Apply Filter

Today


News

Johnson & Johnson loses pelvic mesh class action in Australia

JNJ

MELBOURNE (Reuters) - More than 1,350 Australian women won a seven-year-old class action lawsuit on Thursday against Johnson & Johnson (J&J) for misleading patients and surgeons about the risks of the pharmaceutical giant's pelvic mesh implants. The suit is one of many J&J has faced in the United States, Canada and Europe over the implants, used to treat urinary incontinence and pelvic organ prolapse, in which organs shift from normal positions. Australia's Federal Court found that J&J subsidiary Ethicon had sold the devices without warning women about the "gravity of the risks", and was negligent in rushing the products to market before proper testing. The judge in the case, Anna Katzmann, has set February for the next hearing in the case, where damages will be discussed.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
  • Science

Yesterday


News

Global Transdermal Skin Patches Market 2019 – Johnson & Johnson , Novartis AG , Mylan N.V. , Teva Pharmaceutical Industries – Industry Press Release

GSK JNJ +2 more GSK JNJ GSK RB

The Global Transdermal Skin Patches Market 2019 report offers clear-cut information about the key business-giants Johnson & Johnson. The Global Transdermal Skin Patches Market 2019 report is based on key players, which are combined by market share, history of growth and Industry forecasts, it provides in-detailed information, basic needs of the market, and the report shows the how this market is growing Globally. The main regions that contribute to the worldwide Transdermal Skin Patches Market 2019 are United States, Europe, Japan, China, India, Southeast Asia. Chapter 1, to describe worldwide Transdermal Skin Patches Market 2019 Introduction, product scope, market overview, market opportunities, market risk, market driving force;.

Read Full Details

Topics:
  • Business
  • Financial

Monday, November 18


News

Top Analyst Reports for Alphabet, Amazon & Johnson & Johnson

JNJ GOOGL +2 more JNJ GOOGL AMZN GOOG

Johnson & Johnson’s shares have gained 2% over the past three months against the Zacks Large Cap Pharmaceuticals industry's rise of 6.3%. The Zacks analyst believes that J&J is witnessing significant generic/biosimilar headwinds in the Pharma unit in 2019. However, the unit is performing above-market levels supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara. Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. Per the Zacks analyst, the company's UnitedHeathcare and Optum businesses have been putting up a solid performance from past many years that have led to revenue and membership growth.

Read Full Details

Topics:
  • Business
  • Financial
News

Cough Remedies Market Wrap: Now Even More Attractive (Johnson & Johnson, Reckitt Benckiser, Bayer and many more..) - WindStreetz

JNJ RB +1 more JNJ RB BAYN

The study report is evaluated on two segments i.e types and applications covering all the analytical data for current and future markets. The Cough Remedies market report study also covers the current and future market insights from a detailed analysis of the market across key regions – United States, China, European Union, Rest of World (Japan, Korea, India, and Southeast Asia). The global prominent players operating in the Cough Remedies market are as follows –. – To identify significant trends, drivers, influence factors in global and regions – To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Read Full Details

Topics:
  • Business
  • Financial
  • Science

Saturday, November 16


News

DAGCO Inc. Trims Holdings in Johnson & Johnson (NYSE:JNJ) – Trent Times

JNJ

Johnson & Johnson makes up about 1.9% of DAGCO Inc.’s portfolio, making the stock its 13th largest holding. Adams Diversified Equity Fund Inc. now owns 304,800 shares of the company’s stock valued at $39,435,000 after acquiring an additional 99,900 shares during the period. The company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. Finally, Wells Fargo & Co decreased their price objective on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, November 15


News

Oklahoma judge reduces Johnson & Johnson order in opioid lawsuit by $107 million

JNJ

FILE - In this Aug. 26, 2019 file photo, Judge Thad Balkman reads a summary of his decision in the opioid trial at the Cleveland County Courthouse in Norman, Okla. Judge Balkman reduces amount Johnson & Johnson must pay state to help clean up opioid crisis by $107 million to $465 million on Friday Nov. 15, 2019. The judge declined a request by the defendants to further reduce the amount to take into account pre-trial settlements totaling $355 million the state reached with Oxycontin-maker Purdue Pharma and Israeli-owned Teva Pharmaceuticals. Attorneys for Johnson & Johnson said the company plans to appeal Balkman’s ruling to the Oklahoma Supreme Court. Following a seven-week trial this summer, Balkman ruled Johnson & Johnson and its subsidiaries helped fuel the opioid crisis with an aggressive and misleading marketing campaign that overstated how effective the drugs were for treating chronic pain and understated the risk of addiction.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Entertainment
News

Global Baby Care Products Market 2019 Development Status - Artsana, Beiersdorf, Johnson & Johnson, Pigeon - Montana Ledger

JNJ BEI

Recent research analysis from Fior Markets titled Global Baby Care Products Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 clarifies the past movement and patterns considering past encounters to offer a future estimate with respect to different components affecting the growth rate. Foregoing elements demonstrated in this report such as market dynamics, size, growth, technological trends, competitive landscape, regulatory requirements, and emerging opportunities will help to manufacture the methodology and future arranging of the market and hold a spot in the focused world. Various strategies accepted by the key participants for dealing with the Baby Care Products market includes advancements of a new product, acquirements, deals, joint ventures, and mergers. Global Baby Care Products market rivalry by leading manufacturers, together with using production, cost, earnings (value) and market share for every producer; the best players as Artsana, Beiersdorf, Johnson & Johnson, Pigeon. The study report is bifurcated into the following regions on the basis of topography: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, November 14


News

Global Hand Cream Market 2019 – Beiersdorf , Procter & Gamble , Sanofi , Johnson & Johnson , Unilever – Global News Reports 24

JNJ PG +4 more JNJ PG ULVR BEI SAN UNA

Global Hand Cream Market 2019 – Beiersdorf , Procter & Gamble , Sanofi , Johnson & Johnson , Unilever. , who compete for the success of the business expansion and determine the global and regional market. Download Sample Copy Of Report : http://www.marketresearchstore.com/report/global-hand-cream-market-insights-forecast-to-2025-363863#RequestSample. Chapter 1: Introduction, Definition, Specifications, Classification and Scope the Hand Cream market 2019Chapter 2: Exclusive Summery like Industry chain structure, Manufacturer cost structure, suppliers, etcChapter 3: Displays Trends, Drivers and Challenges of the Hand Cream marketChapter 4: By the study of SWOT analysis it displays sales analysis, investment analysis, market analysis, etcChapter 5: It evaluate the market by segments, by countries and by manufacturers with revenue, share and sales by key countries in these various regions.Chapter 6: Evaluate the leading manufacturers of the Global Hand Cream market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company ProfileChapter 7: Hand Cream Research Findings and Conclusion, Appendix, system and information source.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science
News

Global Penicillin Market 2019 – GSK , Pfizer , Johnson & Johnson , Bayer HealthCare , Abbot Laboratories , Roche Pharmaceuticals – Daily Industry Journal

JNJ PFE

Global Penicillin Market 2019 – GSK , Pfizer , Johnson & Johnson , Bayer HealthCare , Abbot Laboratories , Roche Pharmaceuticals. The Global Penicillin Market 2019 report offers clear-cut information about the key business-giants , GSK. The Global Penicillin Market 2019 report is based on key players, which are combined by market share, history of growth and Industry forecasts, it provides in-detailed information, basic needs of the market, and the report shows the how this market is growing Globally. The main regions that contribute to the worldwide Penicillin Market 2019 are United States, Europe, Japan, China, India, Southeast Asia.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
  • Science

Wednesday, November 13


News

Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?

JNJ

On Oct. 15, Johnson & Johnson (NYSE:JNJ), the healthcare giant, reported Q3 earnings and revenue that beat analysts’ average expectations. Yet, over the past 12 months, JNJ stock is down about 9%. Source: Alexander Tolstykh / Shutterstock.com. Finally,its medical devices business develops and markets products and solutions for surgery, orthopedics, and vision. Although about 60% of Johnson &Johnson’s revenue is U.S.-based, its overseas operations in general and its emerging market businesses in particular are proving to be important growth catalysts for JNJ. JNJ’s short-term charts are painting a mixed picture and suggest that JNJ stock is likely to trade within a range. While long-term investors would like to see JNJ stock stay over $135, short-term traders are likely to keep the shares between $125 and $135. I remain bullish on the long-term outlook of Johnson and Johnson stock. However, in the short-term, JNJ might exhibit weakness. Therefore, investors may consider staying on the sidelines on JNJ if they do not currently have a position in the shares.

Read Full Details

Topics:
  • Business
  • Financial